Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance

a technology of liposomes and antigens, which is applied in the direction of antibacterial agents, dsdna viruses, antibacterial ingredients, etc., can solve the problems of not teaching or suggesting combining antigens, and achieve the effect of increasing antibody titers and increasing the percentage of activated or memory cd8+

Inactive Publication Date: 2011-03-24
IMMUNOVACCINE TECH INC
View PDF103 Cites 23 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0004]Applicants have now discovered that a composition comprising an antigen, a polyI:C polynucleotide, liposomes and a carrier comprising a continuous phase of a hydrophobic substance may provide surprisingly higher antibody titers and a higher percentage of activated or memory CD8+ T cells than either conventional vaccine compositions containing polyI:C polynucleotides in an aqueous carrier, or compositions comprising liposomes, a hydrophobic carrier and an alum adjuvant.

Problems solved by technology

However, to Applicants' knowledge, the art does not teach or suggest combining an antigen, a polyI:C polynucleotide, liposomes and a hydrophobic carrier in a vaccine composition.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
  • Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
  • Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0133]Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

[0134]The H5N1 recombinant hemagglutinin protein, was purchased from Protein Sciences (Meridien, Conn., USA). This recombinant protein has an approximate molecular weight of 72,000 daltons and corresponds to the hemagglutinin glycoprotein, an antigenic protein present on the surface of the H5N1 influenza virus. This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 30 microliter dose.

[0135]Vaccine efficacy was assessed by enzyme-linked immunosorbent assay (ELISA), a method that allows the detection of antigen-specific antibody levels in the serum of immunized animals. Performing the ELISA on sera collected from immunized mice on a r...

example 2

[0141]Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

[0142]As in example 1, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, Conn., USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 30 microliter dose.

[0143]To formulate the vaccine corresponding to the invention, the same procedures as described in example one were used. In summary, 33 micrograms of rHA were suspended in 300 microliters of phosphate buffered saline (pH 7.4) then added to 132 milligrams of a S100 lecithin / cholesterol mixture (Lipoid GmbH, Germany) to form approximately 450 microli...

example 3

[0146]Pathogen free, female CD1 mice, 6-8 weeks of age, were obtained from Charles River Laboratories (St Constant, QC, Canada) and were housed according to institutional guidelines with water and food ad libitum, under filter controlled air circulation.

[0147]As in examples 1 and 2, H5N1 recombinant hemagglutinin protein, corresponding to the hemagglutinin glycoprotein on the surface of the H5N1 influenza virus, was purchased from Protein Sciences (Meridien, Conn., USA). This recombinant protein, hereafter designated rHA, was used as a model antigen to test the efficacy of vaccine formulations. rHA was used at 1 microgram per 50 microliter dose.

[0148]To formulate vaccine corresponding to the invention, a 10:1 w:w homogenous mixture of S100 lecithin and cholesterol (Lipoid GmbH, Germany) was hydrated in the presence of a rHA and polyI:C adjuvant (Pierce, Rockford, Ill., USA) solution in phosphate buffer to form liposomes with encapsulated rHA and adjuvant. In brief, 20 micrograms of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a composition comprising: an antigen; liposomes; a polyI:C polynucleotide; and a carrier comprising a continuous phase of a hydrophobic substance. Methods for making and using the compositions are also provided.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of and priority from U.S. Provisional Patent Application No. 61 / 059,043, filed Jun. 5, 2008.FIELD OF THE INVENTION[0002]The present application relates compositions comprising liposomes, an antigen, a polyI:C polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance, and their use.BACKGROUND OF THE INVENTION[0003]Conventional vaccines may comprise an antigen, an adjuvant and a pharmaceutically acceptable carrier. It is known that a polyI:C polynucleotide may be useful as an adjuvant. It is also known that liposomes may be useful in vaccine compositions (see Applicants' issued U.S. Pat. No. 6,793,923). However, to Applicants' knowledge, the art does not teach or suggest combining an antigen, a polyI:C polynucleotide, liposomes and a hydrophobic carrier in a vaccine composition.SUMMARY OF THE INVENTION[0004]Applicants have now discovered that a composition comprising an antigen...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K9/127A61P31/04A61P31/10A61P31/12A61P33/00A61P35/00A61P31/16A61P25/28A61K39/145A61K39/00A61K39/12
CPCA61K9/10A61K9/107A61K9/127A61K9/19A61K2039/55561A61K39/00A61K47/06A61K2039/55555A61K31/785A61K39/39A61K39/12C12N2710/20034A61P31/20A61P31/16C12N2760/16134A61K2039/55566A61K2039/55505A61K2039/55544A61K39/0007A61K2039/575A61P35/00A61P25/28Y02A50/30
Inventor MANSOUR, MARCSAMMATUR, LEELADHARMACDONALD, LISA DIANAKARKADA, MOHANWEIR, GENEVIEVE MARYFUENTES-ORTEGA, ANTAR
Owner IMMUNOVACCINE TECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap